BRODSKY & SMITH INVESTOR ALERT: Updates on Ongoing Investigations for scPharmaceuticals Inc. (Nasdaq – SCPH), Vital Energy, Inc. (NYSE – VTLE), International Money Express, Inc. (Nasdaq - IMXI), and HanesBrands Financial Corp. (NYSE - HBI) | Intellectia.AI
BRODSKY & SMITH INVESTOR ALERT: Updates on Ongoing Investigations for scPharmaceuticals Inc. (Nasdaq – SCPH), Vital Energy, Inc. (NYSE – VTLE), International Money Express, Inc. (Nasdaq - IMXI), and HanesBrands Financial Corp. (NYSE - HBI)
Written by Emily J. Thompson, Senior Investment Analyst
Investigation Announcements: Brodsky & Smith is reminding investors about ongoing investigations related to several companies, including scPharmaceuticals, Vital Energy, International Money Express, and HanesBrands, regarding potential breaches of fiduciary duties by their boards.
scPharmaceuticals Acquisition: scPharmaceuticals is set to be acquired by MannKind Corporation for $5.35 per share in cash plus milestone payments, raising concerns about whether the deal offers fair value to shareholders.
Vital Energy Merger Details: Vital Energy will merge with Crescent Energy in an all-stock transaction valued at approximately $3.1 billion, with investigations focusing on whether the deal consideration is fair compared to the company's 52-week high stock price.
HanesBrands Sale Terms: HanesBrands is being acquired by Gildan Activewear, offering shareholders a combination of cash and stock, but investigations are questioning if this offer reflects fair value given its lower comparison to the company's recent stock highs.
Wall Street analysts forecast IMXI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMXI is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast IMXI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMXI is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
2 Hold
0 Sell
Hold
Current: 15.500
Low
16.00
Averages
16.00
High
16.00
Current: 15.500
Low
16.00
Averages
16.00
High
16.00
Northland
Mike Grondahl
Outperform -> Market Perform
downgrade
$16
Al Analysis
2025-08-11
Reason
Northland
Mike Grondahl
Price Target
$16
Al Analysis
2025-08-11
downgrade
Outperform -> Market Perform
Reason
Northland analyst Mike Grondahl downgraded Intermex (IMXI) to Market Perform from Outperform with a $16 price target after Western Union (WU) announced a deal to acquire Intermex in an all-cash transaction at $16.00 per share.
UBS
Neutral
downgrade
$17 -> $12
2025-05-09
Reason
UBS
Price Target
$17 -> $12
2025-05-09
downgrade
Neutral
Reason
UBS lowered the firm's price target on Intermex to $12 from $17 and keeps a Neutral rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMXI
Unlock Now
BMO Capital
Outperform -> Market Perform
downgrade
$18 -> $11
2025-05-08
Reason
BMO Capital
Price Target
$18 -> $11
2025-05-08
downgrade
Outperform -> Market Perform
Reason
BMO Capital downgraded Intermex to Market Perform from Outperform with a price target of $11, down from $18. The company reported a "broad-based" Q1 miss, the analyst tells investors in a research note. The retail remittance market remains under pressure, while a new shift in customer behavior has emerged, reduced transaction frequency, that is pressuring Intermex to a degree not previously contemplated, the analyst tells investors in a research note. The firm adds the company's accelerating investment in digital marketing, while a longer-term positive, implies further near-term headwinds for EBITDA margins. BMO worries about additional downside risk to Intermex's revised fiscal 2025 guidance. Further, the likelihood of a take-private transaction following the conclusion of its strategic review "is now significantly lower," adds the firm.
Needham
Mayank Tandon
Strong Buy
Reiterates
$20
2025-04-07
Reason
Needham
Mayank Tandon
Price Target
$20
2025-04-07
Reiterates
Strong Buy
Reason
About IMXI
International Money Express, Inc. is an omnichannel money remittance services company. The Company applies proprietary technology enabling consumers to send money from the United States, Canada, Spain, Italy, the United Kingdom and Germany to more than 60 countries. It offers the digital movement of money through a network of agent retailers in the United States, Canada, Spain, Italy, the United Kingdom and Germany; Company-operated stores; its mobile apps, and the Company’s Websites. Its remittance services include a suite of ancillary financial processing solutions and payment services, which are available in all 50 states in the United States, Washington D.C., Puerto Rico and 13 provinces in Canada. Its product and service portfolio includes online payment options, pre-paid debit cards and direct deposit payroll cards. Its money remittance services are also available on the Internet via its Websites (intermexonline.com and online.i-transfer.es) and on mobile device applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
